- Home
- STRW vs ADCT Comparison
STRW vs ADCT Comparison
Compare STRW & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- ADCT
- Stock Information
- Founded
- STRW 2015
- ADCT 2011
- Country
- STRW United States
- ADCT Switzerland
- Employees
- STRW N/A
- ADCT N/A
- Industry
- STRW Real Estate Investment Trusts
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- ADCT Health Care
- Exchange
- STRW Nasdaq
- ADCT Nasdaq
- Market Cap
- STRW 133.6M
- ADCT 127.9M
- IPO Year
- STRW N/A
- ADCT 2020
- Fundamental
- Price
- STRW $10.15
- ADCT $1.28
- Analyst Decision
- STRW Strong Buy
- ADCT Strong Buy
- Analyst Count
- STRW 4
- ADCT 5
- Target Price
- STRW $13.83
- ADCT $7.75
- AVG Volume (30 Days)
- STRW 45.5K
- ADCT 235.3K
- Earning Date
- STRW 05-09-2025
- ADCT 05-14-2025
- Dividend Yield
- STRW 5.47%
- ADCT N/A
- EPS Growth
- STRW 34.22
- ADCT N/A
- EPS
- STRW 0.58
- ADCT N/A
- Revenue
- STRW $126,557,000.00
- ADCT $70,837,000.00
- Revenue This Year
- STRW $15.21
- ADCT $6.82
- Revenue Next Year
- STRW $2.21
- ADCT $18.56
- P/E Ratio
- STRW $17.34
- ADCT N/A
- Revenue Growth
- STRW 22.41
- ADCT 1.84
- 52 Week Low
- STRW $8.70
- ADCT $1.05
- 52 Week High
- STRW $12.90
- ADCT $4.83
- Technical
- Relative Strength Index (RSI)
- STRW 41.28
- ADCT 43.00
- Support Level
- STRW $10.00
- ADCT $1.23
- Resistance Level
- STRW $11.50
- ADCT $1.49
- Average True Range (ATR)
- STRW 0.68
- ADCT 0.08
- MACD
- STRW -0.06
- ADCT 0.00
- Stochastic Oscillator
- STRW 15.09
- ADCT 25.00
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).